Oneness Biotech Co (LUX:ONEA) Net Interest Margin (Bank Only) %

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LUX:ONEA Oneness Biotech Co Ltd LUX:ONEA
59 GF Score
Price $23.60
GF Value $35.65
! 4 Warning Signs
View Full Analysis

What is Oneness Biotech Co Net Interest Margin (Bank Only) %?

Net Interest Margin (Bank Only) % only applies to banks.

LUX:ONEA
59GF Score
Oneness Biotech Co Ltd LUX:ONEA
Net Interest Margin (Bank Only) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Oneness Biotech Co (LUX:ONEA) Overvalued in 2026?

Based on GuruFocus' analysis, Oneness Biotech Co stock appears to be undervalued. The current stock price of $23.60 is trading 33.8% below its estimated GF Value™ of $35.65.

Key valuation signals for LUX:ONEA:

  • Net Interest Margin (Bank Only) %:
  • GF Value™: $35.65 vs. price of $23.60 (33.8% below fair value)
  • GF Score™: 59/100 with 4 warning signs

No single metric tells the full story. See the LUX:ONEA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Oneness Biotech Co Business Description

Other Exchanges 4743:Taiwan
Address Zhongxiao West Road, No. 66, 35th Floor, Section 1, Zhongzheng District, Taipei, TWN, 100
Oneness Biotech Co Ltd is engaged in the research and development of new drugs, the sale of pharmaceutical products and health products, and other related businesses. It focuses on developing drugs for the treatment of chronic skin and immune diseases. The Group's product portfolio comprises FESPIXON cream, for the treatment of diabetic foot ulcers, and Bonvadis, a wound care medical device. It also has various other product candidates in its development pipeline, such as FB825, FB704A, SNS812, SNS851, and others. The Group operates in the following reportable segments: New drug research and development, which derives maximum revenue, and the Agricultural products cultivation and organic food segment.
59GF Score

Get the complete analysis for LUX:ONEA

Net Interest Margin (Bank Only) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$23.60
Price
$35.65
GF Value